Publications

5674 Results

EA8185: Phase 2 Study of Bladder-SparIng ChemoradiatioN (chemoRT) with Durvalumab in Clinical Stage III, Node PosItive URothElial Carcinoma (INSPIRE), an ECOG-ACRIN/NRG Collaboration

Authors
M Joshi;S Kim;A Solanki;D Miyamoto;D Degraff;J Zou;J Meeks;T Mitin;S Collins;E Trabulsi;N Hahn;J Efstathiou;M Carducci
Journal / Conference
J Clin Oncol 40, 2022 (suppl 16; abstr TPS4617), poster 98B; ASCO Annual Meeting (June 3-7, 2022, Chicago, IL)
Year
2022
Research Committee(s)
Genitourinary
Study Number(s)
CTSU/EA8185

Improving Patient Advocacy in NCI Scientific Steering Committees and Task Forces

Authors
R Bangs;J Lynn;E Obot;S Osborne;K Norris
Journal / Conference
Journal of the National Cancer Institute Aug 8;114(8):1059-1064
Year
2022
Research Committee(s)
Cancer Care Delivery
PMID
PMID35552713
PMC
PMC9360467

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small Cell Lung Cancer Previously Treated with Immunotherapy—Lung-MAP S1800A

Authors
K Reckamp;M Redman;K Dragnev;L Villaruz;B Faller;T Al Baghdadi;S Hines;L Everhart;L Highleyman;K Minichiello;V Papadimitrakopoulou;J Neal;S Waqar;S Waqar;J Patel;J Gray;D Gandara;K Kelly;R Herbst
Journal / Conference
Journal of Clinical Oncology Jul 20;40(21):2295-2306
Year
2022
Research Committee(s)
Lung
PMID
PMID35658002
PMC
PMC9287284
Study Number(s)
S1800A

Randomized Phase II Trial Of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma (MIUC): SWOG Gap Trial (S2011)

Authors
G Sonpavde;M Plets;M Liss;J Meeks;D Petrylak;S Cole;R McKay;S Gupta;S Hita;T Pereira;R Bangs;C Tangen;IM Thompson;SP Lerner
Journal / Conference
JCO Vol 40 Issue 6 Supp; ASCO Genitourinary (GU) Cancers Symposium 2022 (Feb 17-19, 2022, San Francisco, CA), poster
Year
2022
Research Committee(s)
Genitourinary
Study Number(s)
S2011

Orteronel for metastatic hormone sensitive prostate cancer: A multicenter, randomized, open-label phase III trial (SWOG-1216)

Authors
N Agarwal;C Tangen;M Hussain;S Gupta;M Plets;P Lara;A Harzstark;P Twardowski;C Paller;D Zylla;M Zibelman;E Levine;B Roth;A Goldkorn;D Vaena;M Kohli;A Crispino;N Vogelzang;IM Thompson;DI Quinn
Journal / Conference
Journal of Clinical Oncology Oct 1;40(28):3301-3309
Year
2022
Research Committee(s)
Genitourinary
PMID
PMID35446628
PMC
PMC9553390
Study Number(s)
S1216

A More Efficient Approach to Clinical Trial Data Collection: The SWOG-nCartes Pilot Collaboration

Authors
C Cook;D Weatherbee;A Smith;S Yadav;G Bhardwaj;J Mcllwain;A Hoering;M LeBlanc;K Goodman
Journal / Conference
Society for Clinical Trials (MAY 15-18, 2022 San Diego, CA), poster
Year
2022
Research Committee(s)
Multiple sites

Lessons from Implementing Practice-Level Cluster Randomized Studies within the NCORP Setting

Authors
K Arnold;G Anderson;D Weatherbee
Journal / Conference
Society for Clinical Trials (MAY 15-18, 2022 San Diego, CA), poster
Year
2022
Research Committee(s)
Cancer Care Delivery, Prevention, Screening, and and Surveillance
Study Number(s)
S1415CD, S1904, S2108CD

A non-factorial analysis of a factorial Phase II trial design to evaluate single agent and combination consolidation therapies following CD19 CAR T-cell therapy for relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL): SWOG-S2114

Authors
H Li;M LeBlanc;B Hess;N Hossain;SM Smith;P Stiff;J Friedberg
Journal / Conference
Society for Clinical Trials (MAY 15-18, 2022 San Diego, CA), poster
Year
2022
Research Committee(s)
Lymphoma
Study Number(s)
S2114

Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer

Authors
S Schild;X Wang;C Bestvina;T Williams;G Masters;A Singh;T Stinchcombe;J Salama;S Wolf;T Zemla;N Duma;S Chun;A Amini;D Kozono;C Watt
Journal / Conference
Clinical Lung Cancer Jul;23(5):e317-e320
Year
2022
Research Committee(s)
Lung
PMID
PMID35613998
PMC
PMC9634857
Study Number(s)
A082002

Circulating tumor DNA (ctDNA) kinetics predict progression-free and overall survival in EGFR TKI-treated patients with EGFR-mutant NSCLC (SWOG S1403)

Authors
P Mack;J Miao;M Redman;J Moon;S Goldberg;R Herbst;M Melnick;Z Walther;F Hirsch;K Politi;K Kelly;D Gandara
Journal / Conference
Clinical Cancer Research Sep 1;28(17):3752-3760
Year
2022
Research Committee(s)
Lung
PMID
PMID35713632
PMC
PMC9444942
Study Number(s)
S1403